

# 3C-like-proteinase inhibitors- Pipeline Insight, 2022

<https://marketpublishers.com/r/302331F96220EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: 302331F96220EN

## Abstracts

This report can be delivered to the clients within 24 hours

DelveInsight's, "3C-like-proteinase inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in 3C-like-proteinase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### 3C-like-proteinase inhibitors Understanding

#### 3C-like-proteinase inhibitors: Overview

3C-like-proteinase is a cysteine protease that is excised from polyproteins by its own proteolytic activity and forms a homodimer with one active site per subunit. 3CL pro reportedly recognizes the residues from P4 to P1 on the N-terminal side and P1' on the C-terminal side of the cleavage sites, based on the consensus sequences around the processing sites in the SARS-CoV polyproteins and the extensive mutagenesis analyses of the N-terminal autoprocessing site. 3C-like proteases (3CLpros) from CoVs (also called main proteases) are essential for viral replication and are also involved in polyprotein cleavage and immune regulation, making them attractive and effective targets for the development of antiviral drugs. 3-chymotrypsin-like protease (3CL pro) is considered to be a promising drug target. Various studies are going on to study this

protein in order to identify therapeutics against the SARS-CoV in particular and other pathogenic coronaviruses. A number of patented inhibitors with promising clinical potential have been developed through different methods.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence 3C-like-proteinase inhibitors R&D. The therapies under development are focused on novel approaches for 3C-like-proteinase inhibitors.

## 3C-like-proteinase inhibitors Emerging Drugs Chapters

This segment of the 3C-like-proteinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## 3C-like-proteinase inhibitors Emerging Drugs

### Masitinib: AB Science

Masitinib is an orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, through inhibiting a limited number of kinases. Based on its unique mechanism of action, can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. Masitinib is currently in late-stage development for ALS. Masitinib has received orphan drug designation for ALS from both the European Medicine Agency (EMA) and the U.S. Food and Drug Administration (FDA).

### PF-07304814: Pfizer

PF-07304814 is a small molecule that targets the 3CL protease, an enzyme that coronaviruses use to assemble themselves and multiply. PF-07304814 contains a phosphate group that makes the compound soluble and gets cleaved by alkaline

phosphatase enzymes in tissue, releasing the active antiviral PF-00835231. The potential drug is in Phase I clinical studies for the treatment of COVID 2019 infections.

Further product details are provided in the report.....

### 3C-like-proteinase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different 3C-like-proteinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players working on 3C-like-proteinase inhibitors

There are approx. 8+ key companies which are developing the 3C-like-proteinase inhibitors. The companies which have their 3C-like-proteinase inhibitors drug candidates in the most advanced stage, i.e. Phase III include, AB Science.

#### Phases

DelveInsight's report covers around 8+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

3C-like-proteinase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under

various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and

Mono/Combination.

### 3C-like-proteinase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses 3C-like-proteinase inhibitors therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging 3C-like-proteinase inhibitors drugs.

### 3C-like-proteinase inhibitors Report Insights

3C-like-proteinase inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

### 3C-like-proteinase inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

### Key Questions

## Current Scenario and Emerging Therapies:

How many companies are developing 3C-like-proteinase inhibitors drugs?

How many 3C-like-proteinase inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for 3C-like-proteinase inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the 3C-like-proteinase inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for 3C-like-proteinase inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

AB Science

Pfizer

Aligos Therapeutics

Array BioPharma

Eli Lilly and Company

SOM Biotech

Cortexyme

## Key Products

Masitinib

PF-07304814

ALG-097111

Prexasertib

Eravacycline

Research programme: small molecules

## Contents

Introduction

Executive Summary

### **3C-LIKE-PROTEINASE INHIBITORS: OVERVIEW**

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

### **3C-LIKE-PROTEINASE INHIBITORS – DELVEINSIGHT'S ANALYTICAL PERSPECTIVE**

In-depth Commercial Assessment

3C-like-proteinase inhibitors companies' collaborations, Licensing, Acquisition -Deal Value Trends

### **3C-LIKE-PROTEINASE INHIBITORS COLLABORATION DEALS**

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Masitinib: AB Science

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II/III)

Comparative Analysis



Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

PF-07304814: Pfizer

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

ALG-097111: Aligos Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

**3C-LIKE-PROTEINASE INHIBITORS KEY COMPANIES**

**3C-LIKE-PROTEINASE INHIBITORS KEY PRODUCTS**

**3C-LIKE-PROTEINASE INHIBITORS- UNMET NEEDS**

**3C-LIKE-PROTEINASE INHIBITORS- MARKET DRIVERS AND BARRIERS**

**3C-LIKE-PROTEINASE INHIBITORS- FUTURE PERSPECTIVES AND CONCLUSION**

**3C-LIKE-PROTEINASE INHIBITORS ANALYST VIEWS**

**3C-LIKE-PROTEINASE INHIBITORS KEY COMPANIES**

Appendix

## List Of Tables

### LIST OF TABLES

- Table 1 Total Products for 3C-like-proteinase inhibitors
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for 3C-like-proteinase inhibitors
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: 3C-like-proteinase inhibitors- Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/302331F96220EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/302331F96220EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970